Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01002924 · ClinicalTrials.gov registry record · Phase 2
Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010)
A Phase 2 study, sponsored by Endocyte.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT01002924: Completed Phase 2 study, sponsored by Endocyte.
NCT01002924 is a Phase 2 study that has completed, run by Endocyte. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01002924, a Phase 2 study, has completed, sponsored by Endocyte.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This extension protocol is for those subjects that have completed the allowed duration of participation in an Endocyte-sponsored clinical trial of EC145 (vintafolide) and have continuing evidence of clinical benefit (stable disease or better) at the time that they completed participation in that study.
Interventions
- DRUG EC145
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2009-12-31 |
| Est. Completion | 2013-12-11 |
| Phase | Phase 2 |
What the finished NCT01002924 record still lists
NCT01002924 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which EC145 is the first listed.
NCT01002924 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01002924 about?
NCT01002924 is a clinical study titled "Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010)". This extension protocol is for those subjects that have completed the allowed duration of participation in an Endocyte-sponsored clinical trial of EC145 (vintafolide) and have continuing evidence of clinical benefit (stable disease or better) at the time that they completed participation in that stu...
What is the current status of trial NCT01002924?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2009-12-31. Estimated completion is 2013-12-11.
What interventions are being tested in trial NCT01002924?
The interventions under investigation include: EC145 (DRUG).
Who is sponsoring clinical trial NCT01002924?
This trial is sponsored by Endocyte, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01002924's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI